Tu Jianfei, Ying Xihui, Zhang Dengke, Weng Qiaoyou, Mao Weibo, Chen Li, Wu Xulu, Tu Chaoyong, Ji Jiansong, Huang Yuan
Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, Zhejiang 323000, China.
Department of Pathology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, Zhejiang 323000, China.
Oncotarget. 2017 Dec 4;8(67):111623-111630. doi: 10.18632/oncotarget.22880. eCollection 2017 Dec 19.
Angiogenesis plays a critical role in tumor growth and metastasis. Angiogenic factor with G patch and FHA domains 1 (AGGF1) has been recently identified as a novel initiator of angiogenesis. However, the function and the prognostic values of AGGF1 in hepatocellular carcinoma remain poorly understood. Our aim is to provide more information to assist design the angiogenesis therapy that targets AGGF1 in HCC.
AGGF1-positive frequency in HCC tissues was significantly higher than in peritumor tissues. The high expression of AGGF1 expression in HCC tissue was well associated with the increased expression of VEGF and the high microvessel density (MVD). AGGF1 expression predicts a poor prognosis and AGGF1 was an independent prognostic factor for DFS.
The expression levels of AGGF1, vascular endothelial growth factor (VEGF) and microvessel density (MVD) were identified by immunohistochemistry in 79 HCC tumor tissues and 24 corresponding peritumor tissues. The expression level of AGGF1 and MVD were quantified by counting the positively stained endothelial cells in the HCC and the peritumor tissue on the immunohistochemically stained tissue slides. The prognostic value of AGGF1 was evaluated by survival analysis.
Our study shows that AGGF1 is identified as the independent prognostic factor for the disease-free survival (DFS) of patients after the surgical resection. contribute to tumor angiogenesis in HCC, which indicates that AGGF1 may be a new potential therapeutic target for anti-angiogenesis treatment for patients with HCC.
血管生成在肿瘤生长和转移中起关键作用。含G结构域和FHA结构域的血管生成因子1（AGGF1）最近被鉴定为一种新型血管生成启动因子。然而，AGGF1在肝细胞癌中的功能和预后价值仍知之甚少。我们的目的是提供更多信息，以协助设计针对肝癌中AGGF1的血管生成治疗方案。
肝癌组织中AGGF1阳性频率显著高于癌旁组织。肝癌组织中AGGF1的高表达与VEGF表达增加和微血管密度（MVD）升高密切相关。AGGF1表达预示预后不良，且AGGF1是DFS的独立预后因素。
采用免疫组织化学法检测79例肝癌肿瘤组织及24例相应癌旁组织中AGGF1、血管内皮生长因子（VEGF）和微血管密度（MVD）的表达水平。通过对免疫组织化学染色组织切片上肝癌及癌旁组织中阳性染色的内皮细胞进行计数，定量AGGF1表达水平和MVD。通过生存分析评估AGGF1的预后价值。
我们的研究表明，AGGF1被确定为手术切除后患者无病生存（DFS）的独立预后因素。AGGF1促进肝癌肿瘤血管生成，这表明AGGF1可能是肝癌患者抗血管生成治疗的一个新的潜在治疗靶点。
